Any current/future new fundraising through debt or equity?

The company mentioned becoming debt-free post IPO and realized annualized cost savings of about Rs. 40 crores on interest. There was no explicit mention of any new fundraising plans through debt or equity during the call. The focus is currently on capital expenditure funded through internal cash flows, targeting expansions such as Dombivli and the new Pune hospital. Future plans include acquiring land for another hospital to deploy generated free cash flow. No specific plans or discussions of additional debt or equity fundraising were disclosed as of the Q4 FY24 call on May 13, 2024.

Any current/future capex/capital investment/strategic investment?

**Dombivli Hospital:** Construction progressing as planned; project completion expected by Q4 FY26. Estimated CAPEX ~Rs 300 crores for FY25 and FY26. **New Pune Hospital:** Land secured in South Pune (3 acres), structured as a 10-year flat lease with right to buy after 3 years, enabling CAPEX deferral. Planned 500 beds with Phase 1 commissioning ~250 beds. Estimated CAPEX ~Rs 200-250 crores for FY25 and FY26. **Indore Facility:** Adding 75 beds by building two additional floors, costing about Rs 20 lakhs per bed (~Rs 15 crores). Potential to add 200 more beds as land available. **Pune Hospi

Future growth expectations in sales/revenue/volumes?

Jupiter Life Line aims to double its bed capacity to 2,500 beds in the next five years, indicating significant expansion and revenue growth potential. New projects include a 500-bed hospital in South Pune and expansions of 75 beds in Indore and 22 beds in Pune. Dombivli hospital project (400-500 beds) expected to ramp up over the next 2 years; initial EBITDA loss estimated at Rs 2-3 crores per month during the first 12 months due to occupancy ramp-up. Occupancy at existing hospitals like Pune expected to grow from current ~62% to mid-70%. Annual price increases of around 5% for self-paying pat

Future growth expectations in earnings/operating earnings/profits/EPS?

Jupiter Life Line aims to double its size to 2,500 beds over the next five years, signaling significant capacity growth. Expansion includes a new 500-bed hospital in Pune and a 75-bed addition in Indore, with further potential increases planned. Expected inflation-linked growth in ARPOB (Average Revenue Per Occupied Bed) across most hospitals. Occupancy rates expected to improve, e.g., Pune’s occupancy projected to grow from 62% to mid-70%. New facilities like Dombivli may see initial EBITDA losses around Rs 2-3 crores per month in the first year but expected to break even within 2 years. Cost

Jupiter Life LinQ4 FY24Healthcare Services

Jupiter Life Lin Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹260P/E: 45.6Market Cap: ₹8.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Jupiter Life Line aims to double its bed capacity to 2,500 beds in the next five years, indicating significant expansion and revenue growth potential.
New projects include a 500-bed hospital in South Pune and expansions of 75 beds in Indore and 22 beds in Pune.
Dombivli hospital project (400-500 beds) expected to ramp up over the next 2 years; initial EBITDA loss estimated at Rs 2-3 crores per month during the first 12 months due to occupancy ramp-up.
Occupancy at existing hospitals like Pune expected to grow from current ~62% to mid-70%.
Annual price increases of around 5% for self-paying patients are planned, supporting ARPOB growth.
Growth will be driven by higher volumes from capacity additions and inflation-linked price hikes.
Emphasis is on urban Western India with plans to secure land and build more hospitals to deploy future cash flows, further driving revenue growth.

Margin guidance

Category 3

Jupiter Life Line aims to double its size to 2,500 beds over the next five years, signaling significant capacity growth.
Expansion includes a new 500-bed hospital in Pune and a 75-bed addition in Indore, with further potential increases planned.
Expected inflation-linked growth in ARPOB (Average Revenue Per Occupied Bed) across most hospitals.
Occupancy rates expected to improve, e.g., Pune’s occupancy projected to grow from 62% to mid-70%.
New facilities like Dombivli may see initial EBITDA losses around Rs 2-3 crores per month in the first year but expected to break even within 2 years.
Cost savings of Rs 40 crores realized post-IPO due to becoming debt-free, improving net margins.
Overall, EBITDA margins remain healthy (~22.6% FY24), with operating income growth around 19.9% YoY, indicating robust earnings growth.
Strategic focus on Western India with targeted cash flow deployment for new projects suggests sustained profit and EPS expansion.

See what Jupiter Life Lin management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company mentioned becoming debt-free post IPO and realized annualized cost savings of about Rs. 40 crores on interest.
There was no explicit mention of any new fundraising plans through debt or equity during the call.
The focus is currently on capital expenditure funded through internal cash flows, targeting expansions such as Dombivli and the new Pune hospital.
Future plans include acquiring land for another hospital to deploy generated free cash flow.
No specific plans or discussions of additional debt or equity fundraising were disclosed as of the Q4 FY24 call on May 13, 2024.

Order book

The transcript does not explicitly mention any current or expected order book or pending orders for Jupiter Life Line Hospitals Limited. However, from the discussion, some key growth and expansion plans include: - Signed new land for a second hospital in Pune with 500 beds planned. - Planning to add 75 beds in Indore, with potential to add 200 more beds on excess land. - Dombivli hospital construction progressing, expected completion by Q4 FY26. - CAPEX plans include around Rs. 300 crores for Dombivli and Rs. 200-250 crores for the new Pune hospital in FY25 and FY26, totaling about Rs. 600 crores. - Intend to secure one more hospital land this year to increase capacity toward 2500 beds. No direct mentions of order book or pending orders specific to supplies or equipment were made during the call.

See what Jupiter Life Lin management said on order book — free account, 30 seconds.

Capex plans

Yes

Dombivli Hospital: Construction progressing as planned; project completion expected by Q4 FY26. Estimated CAPEX ~Rs 300 crores for FY25 and FY26.
New Pune Hospital: Land secured in South Pune (3 acres), structured as a 10-year flat lease with right to buy after 3 years, enabling CAPEX deferral. Planned 500 beds with Phase 1 commissioning ~250 beds. Estimated CAPEX ~Rs 200-250 crores for FY25 and FY26.
Indore Facility: Adding 75 beds by building two additional floors, costing about Rs 20 lakhs per bed (~Rs 15 crores). Potential to add 200 more beds as land available.
Pune Hospital Expansion: Commissioning 22 new suite rooms, estimated CAPEX Rs 10 lakhs per bed (~Rs 2-3 crores).
Overall CAPEX Plan: Approximately Rs 600 crores planned for FY25, covering expansions and upgrades across hospitals.
Future: Target to reach 2500 beds in 5 years; seeking new land to build another hospital in Western India to deploy generated free cash flow.

Track Jupiter Life Lin — get its next earnings analysis in your feed

How does Jupiter Life Lin rank vs peers in Healthcare Services?

Pro feature

ThisJupiter Life Lin

Rev 2Mar 3

See where Jupiter Life Lin sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Jupiter Life Lin rank in Healthcare Services?

Compare Jupiter Life Lin against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Jupiter Life Lin's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →